American Society of Clinical Oncology

SHERPA: White

People

  1. Zelenetz
    Zelenetz
  2. Horwitz
    Horwitz
  3. Wolden
    Wolden
  4. La Quaglia
    La Quaglia
  5. Noy
    Noy
  6. Giralt
    Giralt
  7. Lesokhin
    Lesokhin
  8. Palomba
    Palomba
  9. Cheung
    Cheung
  10. Perales
    Perales

Groups

  1. Center for Hematologic Malignancies (844)
  2. Department of Medicine (704)
  3. Hematologic Malignancies, Division of (674)
  4. Lymphoma (278)
  5. Adult Leukemia (209)
  6. GSK Faculty (195)
  7. Survivorship Research (188)
  8. Pediatric Leukemia (164)
  9. Pediatrics, Department of (149)
  10. Tow Center for Developmental Oncology (TCDO) (125)
Search Within
  1. "Center for Hematologic Malignancies"
Formats
  1. Meeting Abstract (539)
  2. Journal Article (292)
  3. Editorial (5)
  4. Review (5)
  5. Correspondence (2)
  6. Guidelines (1)
Groups
  1. Center for Hematologic Malignancies (844)
  2. Department of Medicine (704)
  3. Hematologic Malignancies, Division of (674)
  4. Lymphoma (278)
  5. Adult Leukemia (209)
  6. GSK Faculty (195)

More Groups

People
  1. Andrew Zelenetz (84)
  2. Steven Horwitz (62)
  3. Suzanne Wolden (60)
  4. David Straus (45)
  5. Michael La Quaglia (42)
  6. Ariela Noy (41)

More People

Years
  1. 2024 (2)
  2. 2023 (53)
  3. 2022 (58)
  4. 2021 (54)
  5. 2020 (46)
  6. 2019 (53)

More Years

Publications
  1. Journal of Clinical Oncology (804)
  2. JCO Precision Oncology (15)
  3. Journal of Oncology Practice (12)
  4. American Society of Clinical Oncology Educational Book (11)
  5. JCO Clinical Cancer Informatics (2)

Results (844)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Lisocabtagene maraleucel in relapsed/refractory mantle cell lymphoma: Primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study
    Journal Article

    Wang, M.; Siddiqi, T.; Gordon, L. I.; Kamdar, M.; Lunning, M.; Hirayama, A. V.; Abramson, J. S.; Arnason, J.; Ghosh, N.; Mehta, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • CML and the WHO: Why?
    Editorial

    Berman, E.; Shah, N. P.; Deninger, M.; Altman, J. K.; Amaya, M.; Begna, K.; Bhatia, R.; Chan, O.; Collins, R.; Curtin, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Extremity rhabdomyosarcoma-An integrated clinicopathologic and genomic study to improve risk stratification
    Journal Article

    de Traux de Wardin, H.; Xu, B.; Dermawan, J. K.; Smith, M. H.; Wolden, S. L.; Antonescu, C. R.; Wexler, L. H.
    JCO Precision Oncology (2023)

    Fulltext@MSK | Save
  • Clinical targeted next-generation panel sequencing reveals MYC amplification is a poor prognostic factor in osteosarcoma
    Journal Article

    Marinoff, A. E.; Spurr, L. F.; Fong, C.; Li, Y. Y.; Forrest, S. J.; Ward, A.; Doan, D.; Corson, L.; Mauguen, A.; Pinto, N.; more...
    JCO Precision Oncology (2023)

    Fulltext@MSK | Save
  • Fecal transplantation in hematopoietic transplantation
    Journal Article

    Peled, J. U.; van den Brink, M. R. M.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • MANIFEST: Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-naive myelofibrosis
    Journal Article

    Mascarenhas, J.; Kremyanskaya, M.; Patriarca, A.; Palandri, F.; Devos, T.; Passamonti, F.; Rampal, R. K.; Mead, A. J.; Hobbs, G.; Scandura, J. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent
    Meeting Abstract

    Kumar, S.; Bachier, C. R.; Cavo, M.; Corradini, P.; Delforge, M.; Janowski, W.; Lesokhin, A. M.; Mina, R.; Paris, L.; Rosiñol, L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CAMMOUFLAGE trial)
    Meeting Abstract

    Berdeja, J. G.; Martin, T. G.; Rossi, A.; Essell, J. H.; Siegel, D. S. D.; Mailankody, S.; Saini, N.; Holmes, H.; Dhakal, B.; Gasparetto, C. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1b study to evaluate the efficacy, safety, and pharmacokinetics of an investigational microbiome therapeutic, SER-155, in adults undergoing hematopoietic stem cell transplantation
    Meeting Abstract

    Ponce, D. M.; Kosuri, S.; Khera, N.; DeFilipp, Z. M.; Lombardo, M. J.; Ford, C. B.; Peled, J. U.; Van Den Brink, M. R. M.; von Moltke, L.; Tejura, B.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI)
    Meeting Abstract

    Atallah, E. L.; Mauro, M. J.; Sasaki, K.; Levy, M. Y.; Koller, P. B.; Sadek, I.; Yang, D.; Ruckel-Kumar, J.; Khan, M. H.; Cortes, J. E.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save